HOCl Wound Irrigation System, per-patient bag and single-use head (Aquaceso variant) — the story so far

How to read this. This is a synthesis, not a new source of truth: every claim it cites carries the tag the candidate file gives it right now, copied not paraphrased, and every line quoted from a deck is quoted verbatim. See docs/narrative-spec.md.

What it was built against. This narrative reads the candidate file as of updated: 2026-10-04. The file holds 212 claims: 94 verified, 98 unconfirmed, 18 unverified (claims 195-212, appended by later artifacts after the Verifier's last pass and not yet checked) and 2 refuted (claims 55 and 153). It also reads the one dossier the candidate links, acute-chronic-wound-cleansing-irrigation, and all three decks. The candidate lists no seeds. check_decks.py reports all three decks current, and none is STALE. All three were built on 2026-10-04 against the current shape. Five sources are behind the tags or behind the shape, and they are disclosed here rather than corrected:

• The candidate's own scoring section and gate check were written over claims 1-118, before the redesign described below. They still describe "the kit" and "the warming option". They have not been re-run against the current shape or against claims 119-212.
• The candidate's Wrap section is still unfilled placeholders.
• claim 64unconfirmed says no domain dossier covers human wound cleansing. The candidate's domains: now lists one, built the same day and recorded in the frontmatter as added by the research stage. claim 64unconfirmed is still unconfirmed and still reads as written.
• Parts of the dossier are framed on the first shape. Its open-questions table still asks whether hypochlorous acid holds its chlorine "when warmed to ~37 °C" and frames the patent question around "a three-nozzle shielded head with a warming bag".
• The Generator's design-rationale note in the candidate file describes the first shape and is left as written by design. The candidate's own flagged note says to read "single-use kit", "closed" and "warming as an option" there as superseded.

None of these sources was edited.

The one-paragraph version

This is a wound-washing system for nurses and other clinicians in US hospitals, outpatient wound clinics, skilled nursing facilities and home health. A bag of salt water, preserved with a small amount of hypochlorous acid, stays with one patient over several dressing changes. At each session a fresh single-use spray head, with three nozzles and a splash shield, is pushed into the bag, and the nurse squeezes a chamber in the head to wash the wound at the pressure wound-care guidance calls for. It began as a referral from a Danish contact, who described an existing irrigation system called "Aquaceso" and proposed hypochlorous acid as its fluid; nobody has yet found who makes Aquaceso, or whether the referrer can use its design. The shape changed on the day it was written up: a sealed, single-use kit with optional warming became a per-patient bag plus a single-use head, because the US regulator's 2023 proposal accepts a preservative only in a wash that is non-sterile or reused within one patient, the one cleared hypochlorous-acid bag is labelled for reuse within one patient, and a bag squeezed by hand only reaches the bottom of the pressure range. What has been checked is mostly the ground around the product — a crowded field of cleared hypochlorous-acid washes, no separate Medicare payment in any setting checked, the pressure range itself — while nothing of the system has been built or tested, and whether an opened bag stays in specification between one patient's sessions is unanswered.

The story so far

Where it came from. This candidate was referred in, not generated. A contact of the owner described "Aquaceso" as a wound irrigation system already on the market: a bag of temperature-controlled water or irrigation fluid, a three-nozzle spray head giving a controlled pressure, and a splash shield. The maker's material is said to claim stable pressure and a better working environment for staff claim 1unconfirmed. The new element the referrer proposed was hypochlorous acid as the irrigant in place of tap water. Two facts have stayed open from the start. No one has identified the maker of Aquaceso or any regulatory record for it, and US name searches return nothing, which proves nothing about records no connector reaches claim 2unconfirmed. And it is an assumption, not a fact, that the referrer can bring the right to make the hardware claim 3unconfirmed.

The problem it sits inside. Wound cleansing is the step at almost every dressing change where fluid lifts debris and exudate off the wound bed, and nurses do it far more often than physicians [dossier: acute-chronic-wound-cleansing-irrigation]. The population is large and partly sized: Medicare beneficiaries with any wound rose from 8.2 million to 10.5 million between 2014 and 2019, counting all wound types and people rather than washes claim 34verified claim 35verified. The International Wound Infection Institute's 2022 consensus says passive soaking or swabbing may not cleanse adequately, and that mechanical irrigation at 4-15 pounds per square inch "is recommended" claim 86verified. How often that actually happens in the US is not known. There is no figure for irrigations per wound per year claim 36unconfirmed or for the share of encounters that irrigate under pressure claim 38unconfirmed. The dossier names that gap as its first thinness [dossier: acute-chronic-wound-cleansing-irrigation].

Why hypochlorous acid, and what the label can say. The clinical case for any cleansing solution over saline or water is weak. A 2022 Cochrane review found the effect of tap water against saline on infection and healing uncertain claim 39verified. A 2021 Cochrane review of cleansing in venous leg ulcers found insufficient, very-low-certainty evidence for every agent compared claim 95verified. A 2022 systematic review of antiseptics for chronic wounds found no study of chlorous agents that met its criteria and could not assess hypochlorous acid at all claim 93verified. No randomized trial of 100 or more patients showing a healing benefit was found claim 141unconfirmed. The maker of Vashe has registered a randomized trial against saline in leg ulcers, which is not yet recruiting claim 142verified. So the product is built on the label the cleared hypochlorous-acid washes already carry: mechanical cleansing, with the acid present only to preserve the solution claim 4verified claim 6verified claim 7verified. FDA (US Food and Drug Administration)'s 2023 proposal says a use to "deliver antimicrobials to the wound" may not fall under its device centre claim 121verified. That an infection claim would turn the product into a drug is the Generator's reasoning, not a checked fact claim 10unconfirmed claim 20unconfirmed. The cost of that label is that demand rests on clinicians already believing hypochlorous acid beats saline, and nobody has asked them claim 116unconfirmed.

Why now. No macro-trend seed applies, and the candidate says why: the product has no machine-learning function, no Breakthrough case and no separate payment to accelerate claim 64unconfirmed. What has moved is the product category. Hypochlorous acid is already cleared and sold in 1-3 litre irrigation bags claim 6verified, with a second clearance of that bag in 2026 claim 169verified. New professional-use cleansers keep clearing under the same product code, including Vashe Plus on 2026-08-11 claim 76verified claim 77verified. FDA's 2023 proposal to reclassify liquid wound washes has not been codified as of the eCFR of 2026-09-30 claim 12verified.

The first shape, and why it was chosen. As generated, the product was a closed, single-use kit: a prefilled bag, the head and the shield, sold together for one irrigation, with warming carried as an option to be proven. The Generator's reasoning was that each half alone is weak. The solution alone would be a fifth entrant into a field of cleared hypochlorous-acid washes claim 4verified claim 8verified. The hardware alone is a Class I accessory with old precedents claim 17verified claim 18verified. And FDA had cleared a solution-plus-applicator system as one device, IRRISEPT, first as jet lavage and later as a wound wash claim 13verified claim 14verified.

The shape changed — recorded as a redesign. On 2026-10-04, at the first turn of the front-end loop, the product became what it is now. The desirability deck calls this "the shape recorded in the loop record as a redesign". No failing tag caused it, which is why it is recorded as a redesign rather than as something learned from a failed statement. It was prompted by four verified findings:

• FDA's 2023 proposal would allow an antimicrobial preservative only in "a nonsterile liquid wound wash or a multiple-use liquid wound wash for single patient use only", and it calls a preservative in a sterile, single-use product not appropriate claim 119verified. The first shape was exactly that sterile, single-use product.
• The same proposal lists hypochlorous acid among antimicrobials of low resistance concern, which places such washes in Class II (FDA device class II) rather than Class III (FDA device class III) claim 120verified.
• The one cleared hypochlorous-acid irrigation bag is labelled "Multiple use within a single patient" claim 122verified.
• A hand-compressed IV bag gave a median peak of only 4 pounds per square inch, the bottom of the range claim 143verified. A bag alone cannot reliably drive the head.

The verified chemistry also ran against warming: hypochlorous acid was unstable at 25 C and above claim 96verified, and neutral electrolysed water lost almost all its chlorine at 25 C over 52 days claim 97verified. The current shape therefore has a bag labelled for multiple use within one patient over a stated in-use period. Each session gets a single-use head assembly, stored dry and sterilized separately, carrying its own hand-squeezed chamber refilled through a check valve, with no metal in the wetted path and no pump. The irrigant is used at room temperature. The indications, the settings, the preservative-only label and the pressure range did not change. The two-part architecture, joined by the user at the point of use, is one FDA has cleared before claim 124verified claim 144verified.

Three claims were superseded when the shape changed: the warming question claim 50unconfirmed, the 37 C warming test claim 146unconfirmed and the first shape's unit cost claim 129unconfirmed. Four more were superseded once the chairs restated, each now replaced by a version for the current shape:

• the buyer-premium assumption claim 62unconfirmed, restated as claim 161unconfirmed;
• the Danish tender-lot question for a co-packaged kit claim 138unconfirmed, restated as claim 170unconfirmed and claim 171unconfirmed;
• the first kit's pressure-and-debris study claim 139unconfirmed, restated as claim 172unconfirmed;
• the first kit's splatter study claim 140unconfirmed, restated as claim 173unconfirmed.

All seven stay in the file, in place, with their tags unchanged.

What the redesign cost, and what it opened. It cost the patient something verified: in two randomized trials, patients preferred warmed saline, or had less pain and anxiety with it, with no difference in wound outcomes where outcomes were measured claim 175verified. It also moved the product further from the hardware the referrer described, which warms its fluid claim 1unconfirmed. And it opened new questions the first shape never had:

• how long an opened bag stays in specification while a new head re-enters it at every session claim 167unconfirmed claim 174unconfirmed claim 177unconfirmed;
• whether that in-use period covers the gap between one patient's sessions in every setting claim 189unconfirmed, and in outpatient clinics specifically claim 163unconfirmed. Neither cleared bag's summary states an in-use period claim 169verified;
• whether the head can be keyed to fit only this maker's bag in a way FDA accepts claim 195unverified, and whether buyers will stock such a head claim 162unconfirmed;
• whether staff keep an opened bag with its patient claim 205unverified, and whether infection-prevention committees approve a bag re-entered at every session claim 206unverified.

What has been checked since. Much of the ground around the product is verified, and most of it describes constraints:

• Regulatory. The wound-wash route is open by 510(k) (premarket notification), on bench data alone claim 7verified. Vashe Plus cleared with a 7-day simulated multi-use test and "No clinical data was required" claim 178verified. How FDA would classify the separately sold head is FDA's call and is open claim 180unconfirmed claim 19unconfirmed.
• Payment. Every separately payable channel checked is closed. Wound cleansers are non-covered under the Medicare surgical dressing benefit claim 29verified. Hospital outpatient payment packages supplies claim 65verified, skilled nursing per diems are payment in full claim 66verified, and the home health episode is payment in full claim 67verified.
• Market size. It is not computable: there is a Medicare debridement count that is a floor, not a count of washes claim 68verified, and there are comparator prices that are not this product's price claim 69verified claim 105verified claim 109verified.
• Incumbents. They are consolidating and contracting: Mölnlycke bought Granudacyn's maker claim 110verified, and Urgo holds group-purchasing and federal-supply contracts for Vashe claim 103verified claim 104verified.
• Patents. The live landscape has been read down to claim text in places, listed under "What's solid" below. Two of the file's own patent lookups were wrong and are refuted claim 55refuted claim 153refuted.

What has not been checked. Nothing of the system has been built, so there is no stability, pressure, splash or materials data for it claim 63unconfirmed. No US buyer, nurse, ordering clinician or infection-prevention lead has been asked anything claim 161unconfirmed claim 116unconfirmed. Every European and Danish line is unconfirmed, because no connector in this repo reaches those jurisdictions, and the US work does not stand in for them claim 21unconfirmed claim 25unconfirmed.

What's solid

Only verified claims. Most of what is solid here is a precedent, a range or an obstacle. It describes what the product has to meet, not that it meets it.

The regulatory ground

• Five hypochlorous-acid wound washes are cleared under the unclassified wound-wash product code, each describing a mechanical mechanism with the acid as a preservative: Vashe claim 4verified claim 5verified, Puracyn Plus claim 6verified, CleanSmart claim 7verified, Granudacyn claim 8verified. The product code is unclassified and cleared through 510(k) claim 9verified.
• Vashe Plus cleared on 2026-08-11 for cleansing, irrigating and debriding the same wound types claim 76verified, and other professional-use cleansers cleared in 2025-2026 claim 77verified.
• FDA's 2023 proposed rule exists claim 11verified and had not been codified as of the eCFR of 2026-09-30 claim 12verified. It would limit preservatives to non-sterile or multiple-use single-patient washes claim 119verified. It lists hypochlorous acid as low resistance concern, which means Class II claim 120verified. It names "deliver antimicrobials to the wound" as a use that may fall outside the device centre claim 121verified. For multiple-use washes, its proposed special controls call for worst-case simulated-use preservative testing on three real-time-aged lots claim 176verified.
• The one cleared hypochlorous-acid bag is labelled for multiple use within a single patient claim 122verified. Its 2026 clearance states no in-use period, and records compatibility with three powered lavage systems claim 169verified. Its test list is on record claim 125verified.
• Cleared irrigation systems already ship as two separately sterilized parts joined at the point of use claim 124verified claim 144verified. The 2024 IRRISEPT clearance describes no spray head or splash guard as part of the cleared device claim 123verified.
• The hardware precedents: jet lavage is Class II and exempt subject to limits claim 15verified; the irrigating syringe is Class I and exempt claim 17verified; a splash shield is cleared as a syringe accessory claim 18verified; IRRISEPT's squeeze bottle with a multi-port splashguard was cleared as jet lavage claim 13verified and later as a wound wash claim 14verified; IRRIGO, a hand-squeezed 60 mL bottle reaching up to 15 pounds per square inch, cleared on bench testing with no clinical testing reported claim 16verified claim 179verified.
• Vashe Plus cleared with preservative testing that included a 7-day simulated multi-use period, a porcine wound study and no clinical data claim 178verified.

Payment

• The supply code for wound cleansers exists claim 28verified and is non-covered under the Medicare Part B (Medicare Part B) surgical dressing benefit claim 29verified.
• Supplies are paid inside the bundle in hospital outpatient care claim 65verified, skilled nursing facilities claim 66verified and home health claim 67verified. Office and home services carry non-facility practice-expense units claim 164verified.

Market and competition

• 10.5 million Medicare fee-for-service beneficiaries had a wound in 2019, and 8.2 million in 2014 claim 34verified claim 35verified.
• Medicare Part B practitioner debridement services in 2024 give a floor, not a count of washes claim 68verified.
• Comparator prices, none of them this product's: Medicare allowed amounts for saline and an irrigation syringe claim 69verified; one retailer's list prices for Vashe and Puracyn Plus on one day, both unavailable to buy claim 105verified; one institution's pulsed-lavage protocol cost claim 109verified.
• Urgo holds a Premier group-purchasing agreement claim 103verified and a Federal Supply Schedule contract for Vashe claim 104verified, with no price disclosed. Sonoma's total US revenue across all products was $2.611 million in fiscal 2025 claim 106verified. Mölnlycke completed its acquisition of Granudacyn's maker in 2025 claim 110verified.
• One US burn centre used hypochlorous acid as the initial antiseptic in 11.3% of grafted patients, with no difference in infection claim 107verified. A Canadian nurse survey reports cleansing practice but no share of pressurised irrigation claim 108verified.

Mechanism and safety

• The pressure range: the 2022 consensus recommends 4-15 pounds per square inch claim 86verified, and an FDA summary carries the same range as a predicate attribute claim 70verified.
• The experimental basis: 15 pounds per square inch removed 84.8% of soil infection-potentiating factors claim 88verified; low-pressure bulb irrigation did not cleanse claim 89verified; high pressure spread fluid into tissue claim 90verified; 20 pounds per square inch pulsatile lavage caused muscle damage that bulb-syringe irrigation did not claim 102verified.
• The threshold is not steep: 1.6 and 8.8 pounds per square inch were equally effective in rat wounds claim 91verified, and a large open-fracture trial found no effect of pressure on reoperation claim 92verified.
• A hand-compressed bag peaks at a median 4 pounds per square inch claim 143verified.
• A shielded syringe cut splatter on the irrigator's face and chest in a 1993 model claim 101verified. Federal workplace rules require masks with eye protection wherever splash can be anticipated claim 48verified.
• Aerosol evidence by analogy only: hypochlorous-acid fog harmed cultured cells at 500 ppm but not at 300 ppm claim 99verified; sprayed hypochlorite left chlorine below detection in surface disinfection claim 100verified.
• Chemistry: hypochlorous acid is unstable at 25 C and above and in light and air claim 96verified; neutral electrolysed water lost almost all chlorine over 52 days at 25 C claim 97verified; concentrated alkaline hypochlorite stayed stable when heated, a different chemistry claim 98verified.
• The clinical evidence gap is itself verified: no eligible hypochlorous-acid trial in chronic wounds claim 93verified, insufficient evidence for any agent in venous leg ulcers claim 95verified, tap water against saline uncertain claim 39verified. The withdrawal of older antiseptics from open wounds names traditional hypochlorite, not preserved hypochlorous-acid solutions claim 87verified. An outbreak investigation tied pulsatile lavage to a resistant organism claim 94verified. Patients preferred warmed saline, or had less pain and anxiety with it, with no difference in wound outcomes where measured claim 175verified. The Vashe-against-saline trial is not yet recruiting claim 142verified.

Patents, as database states and claim text, not as an opinion on freedom to operate

• Solution side: Urgo's stabilized-hypohalous-acid family is in force claim 52verified; its claim 1unconfirmed is limited to bicarbonate- or carbonate-stabilized electrolysed acid in a sealed container claim 149verified. Sonoma's claim 1unconfirmed is limited to pH 5.6 with a phosphate buffer claim 150verified. Older Oculus families are lapsed claim 84verified, and some method patents are in force claim 85verified.
• Head and shield: the Schultz splash-shield family was first recorded as live on naive terms running into the 2030s claim 56verified. Later readings counted from its priority chain: its utility patents end before 2032-12-31 claim 152verified. Their independent claims recite a fluid source connector, not a squeeze bottle or syringe claim 181verified. Two of the family have already expired on their priority chains claim 151verified claim 182verified, and its design patents run to about 2037 and 2040 claim 183verified. Medaxis's protective cover is in force claim 156verified and its term runs to about 2038 claim 185verified. Two more irrigation patents are in force with unread claims claim 186verified.
• Features the current shape does not have: every granted CareFusion claim recites warming claim 154verified claim 80verified, and the in-force wound-washing gun claims a battery and pump claim 184verified. CareFusion's pending applications are unread claim 187verified.
• Prior art in the public domain: expired shield patents claim 54verified claim 57verified claim 79verified; a 2008 application on a hypochlorous-acid wound delivery apparatus claim 157verified, whose US members are abandoned claim 83verified; and another abandoned shield application claim 82verified. One containment patent is recorded in force, though the Verifier's note says its term may have ended about 2024 on its 2004 priority chain claim 81verified.

What's still open

Refuted — both about the file's own patent reading

• claim 55refuted named the wrong inventor for an expired shield patent claim 55refuted. Its restatement verifies, and the patent has been lapsed since 2003 claim 79verified. It adds no patent risk, but it is a mark against the Generator's landscape reading.
• claim 153refuted described claim numbers and claim content in two Schultz patents that the grant documents do not contain claim 153refuted. The corrected reading is wider than the refuted one: the independent claims reach any fluid source connector, not only a squeeze bottle or syringe claim 181verified. Any head drawn around those patents has to be drawn from the grant text.

The opened bag

• Room-temperature shelf life claim 126unconfirmed; in-use stability with a new head at each session claim 167unconfirmed; three-lot worst-case simulated use claim 177unconfirmed; organisms introduced at the port not surviving claim 174unconfirmed; the port resealing claim 168unconfirmed; wetted materials holding the solution in specification claim 127unconfirmed.
• Whether the in-use period covers the gap between sessions in every setting claim 189unconfirmed and in outpatient clinics claim 163unconfirmed. A wound-registry study found that diabetic foot ulcers seen at intervals of two weeks or less healed differently from those seen more often, but gave no distribution of visit intervals [dossier: acute-chronic-wound-cleansing-irrigation].
• A formulation outside the Urgo and Sonoma claims that still holds its specification claim 212unverified.
• A recall records a hypochlorous-acid solution corroding the steel spring in its sprayer, found by scan only claim 71unconfirmed. Another records a free-chlorine stability failure in a hydrogel claim 72unconfirmed. Recalls in this category have been for sterility, container integrity, temperature and materials claim 130unconfirmed.

The head

• Delivered pressure within range across the bag's volume claim 145unconfirmed and in every operator's hands, including at maximal grip claim 172unconfirmed.
• Splatter reduction and breathing-zone chlorine claim 173unconfirmed claim 191unconfirmed claim 148unconfirmed; no metal in the fluid path claim 147unconfirmed; squeeze-cycle durability after sterilization claim 192unconfirmed.
• The aerosol question is open claim 51unconfirmed. The dossier found no study that measured clinician exposure during hypochlorous-acid wound irrigation [dossier: acute-chronic-wound-cleansing-irrigation]. A quantitative splash study at the head's pressure has not been found claim 49unconfirmed.
• How FDA would classify it claim 180unconfirmed claim 19unconfirmed, and whether a keyed port is acceptable claim 195unverified.
• Whether a full session can be squeezed by hand without fatigue claim 203unverified. The per-session volume has no figure claim 210unverified.
• No prototype exists claim 63unconfirmed.

Buyers, users and money

• A per-session premium over saline and a syringe claim 161unconfirmed, and its first-shape twins claim 62unconfirmed claim 117unconfirmed; a standard-spike head's version claim 201unverified.
• Formulary acceptance of a keyed head claim 162unconfirmed; channel margin claim 196unverified; no protective equipment displaced claim 197unverified.
• Session cost against price claim 188unconfirmed; the price itself claim 37unconfirmed; the incumbent's federal contract price claim 131unconfirmed; the bag fill as the largest pre-sale cost claim 199unverified; a schedule to first sale claim 194unconfirmed; two independent fillers claim 128unconfirmed; a listing search that found no contract filler of hypochlorous acid in bags claim 190unconfirmed.
• Less hands-on time per session claim 204unverified; ordering clinicians accepting it under existing orders claim 207unverified; custody of the opened bag claim 205unverified; infection-prevention approval claim 206unverified.
• Clinician belief that hypochlorous acid beats saline claim 116unconfirmed.
• Irrigations per wound and the share of encounters that irrigate under pressure claim 36unconfirmed claim 38unconfirmed. A UK count of nurse visits is an analog only claim 111unconfirmed.
• Inpatient bundling claim 136unconfirmed claim 30unconfirmed; a bag sent home outside home health claim 166unconfirmed; device pass-through claim 137unconfirmed; procedure coding claim 31unconfirmed claim 32unconfirmed; cost-in-use as the whole case claim 33unconfirmed; office practice-expense inputs claim 165unconfirmed.
• An incumbent buying or licensing a head claim 202unverified; no incumbent head for its own bag claim 209unverified; the wider competitive landscape claim 60unconfirmed; a scan count of clearances claim 158unconfirmed.

Patents and the referral

• Aquaceso's maker, status and rights claim 2unconfirmed claim 3unconfirmed.
• Landscape negatives claim 155unconfirmed claim 193unconfirmed claim 58unconfirmed; no live claim reading on the head as drawn claim 211unverified; a patentable head claim 208unverified; defensibility resting on hardware claim 59unconfirmed; foundational patents expired claim 53unconfirmed.

Regulatory reasoning and the clinical literature

• The drug-claim line claim 10unconfirmed claim 20unconfirmed; a Drugs@FDA query that found no hypochlorous-acid application claim 78unconfirmed.
• The 1994 pressure guideline itself claim 40unconfirmed and its experimental basis as first written claim 41unconfirmed; the consensus and review claims as first written claim 42unconfirmed claim 43unconfirmed claim 44unconfirmed claim 45unconfirmed claim 46unconfirmed claim 47unconfirmed.
• The dossier adds context that has not become a claim: a 2025 meta-analysis of 12 trials put infection with tap water against saline at a relative risk of 0.78, with an interval crossing 1; a 2024 review found that Dakin's solution "may improve" diabetic-foot healing on low-certainty evidence; and a first-in-human trial of a stabilized hypochlorous-acid product in leg ulcers had safety as its primary endpoint [dossier: acute-chronic-wound-cleansing-irrigation].
• Safety signals reached by scan only: a look-alike packaging report for an antiseptic irrigant used in place of saline claim 73unconfirmed; an aggregate report from one surgeon on IRRISEPT claim 74unconfirmed; a saline wound-wash sterility recall claim 75unconfirmed.

Europe and Denmark — outside the US work, all unconfirmed for lack of a connector

• Classification of the solution and the hardware claim 21unconfirmed claim 24unconfirmed claim 135unconfirmed; the precedents for hypochlorous-acid products claim 22unconfirmed claim 23unconfirmed claim 112unconfirmed; the European landscape claim 61unconfirmed claim 159unconfirmed claim 160unconfirmed.
• Danish buying: tenders claim 25unconfirmed; a Region Nordjylland lot for hypochlorous-acid irrigation fluid, separate from saline claim 113unconfirmed claim 114unconfirmed claim 115unconfirmed; that lot's award criteria, scope and winner claim 132unconfirmed claim 133unconfirmed claim 134unconfirmed; whether the bag alone or the head alone conforms claim 170unconfirmed claim 171unconfirmed; buyer and nurse assumptions claim 26unconfirmed claim 27unconfirmed claim 118unconfirmed; budget claim 198unverified; exclusivity under the awarded lot claim 200unverified.
• From the dossier, not a claim: the tender's estimated-value fields read "27.140" for the hypochlorous-acid lot and "9.760" for the non-hypochlorous lot. Neither the separator convention nor the alignment of values to lots was confirmed [dossier: acute-chronic-wound-cleansing-irrigation].

Superseded by the redesign, kept in place: claim 50unconfirmed claim 62unconfirmed claim 129unconfirmed claim 138unconfirmed claim 139unconfirmed claim 140unconfirmed claim 146unconfirmed.

Where the three lenses agree — and where they don't

All three decks exist. All were built on 2026-10-04 against the current shape, and check_decks.py reports each current, none STALE. They agree on the frame. Nothing of either half has been built. The label rules out any clinical reason to choose the product, so whatever it offers has to be visible at the bedside or on the balance sheet. And most verified claims are constraints rather than backing: each deck counts five or more of its conditions as having nothing verified behind them. Where they differ is on what comes first. Each deck makes a case that its own condition is upstream of the others, and the three cases do not reduce to one.

Desirability (the wound nurse, the ordering clinician, the patient). The deck finds no US clinician has been asked anything, and it adds five conditions of its own to the file, all unverified: hand fatigue, time saved, bag custody, infection-prevention approval and acceptance under existing orders claim 203unverified claim 204unverified claim 205unverified claim 206unverified claim 207unverified. It treats the loss of warming as a verified cost to the patient claim 175verified. Its argument for checking its condition first is that it can be tested on a mock head before any bag exists. It shares one dependency with feasibility. The shield's working-environment benefit, which desirability needs the nurse to see, is the premise that feasibility's breathing-zone chlorine test could invert claim 191unconfirmed.

"whether a US wound nurse, handed the P1 per-patient HOCl bag head in place of the syringe she uses now, would see a per-session advantage she can name without a clinical claim on the label: less hands-on time, or measurably less spray on her face and chest with no chlorine in her breathing zone" — the load-bearing condition of the desirability deck (built 2026-10-04).

Viability (the investor and the operator). The deck finds the payer map settled, and settled as an obstacle. Every intended-use setting buys supplies from inside a bundle, there is no price or market size in the file, and the money is meant to come from the head, which is the half nobody has built claim 161unconfirmed claim 188unconfirmed. It agrees with feasibility that sessions per bag set the cost of each session, and it hands that condition to the feasibility deck. Its argument for checking its condition first is that every other money question sits downstream of a buyer paying more than saline. It disagrees with feasibility on sequence: it treats the bag's in-use period as an input to its own question, not as the question.

"whether US hospital, outpatient wound-clinic, skilled nursing facility and home health buyers, paying from a supply budget inside a bundled payment, would pay more per irrigation session for one P1 per-patient HOCl bag head plus its share of a bag than their saline-and-syringe cost, at a price that clears the fully loaded cost of a session at the business case's volume and at one tenth of it" — the load-bearing condition of the viability deck (built 2026-10-04).

Feasibility (engineering). The deck finds the precedents good for the bag's regulatory route and poor for its chemistry, and finds no direct precedent for the head. It names a tension inside its own lens. The stabilizer that Urgo's claim covers is what keeps hypochlorous acid stable in a container claim 149verified, so a formulation designed around it is the harder bag to make claim 212unverified. Its argument for checking its condition first is that the head has a fallback, a powered head, and the bag does not. If the opened bag fails, the current shape has no label for its preserved bag claim 119verified, and the verified chemistry runs against room-temperature holding claim 96verified claim 97verified.

"whether the opened per-patient bag, re-entered by a new single-use head at every session and kept at room temperature, stays within its free available chlorine, pH and USP <51> specification, with no survival of wound organisms introduced at the port, for an in-use period at least as long as the gap between one patient's sessions in every setting sold to" — the load-bearing condition of the feasibility deck (built 2026-10-04).

The load-bearing question

Can an opened, per-patient bag of hypochlorous-acid-preserved saline, re-entered by a fresh head at every dressing change and kept at room temperature, hold its chlorine, pH and preservative specification, without letting organisms introduced at the port survive, for as long as the gap between one patient's irrigation sessions in each setting it would be sold into?

This is drawn from the feasibility deck's condition, and it is the one the other two lenses lean on without testing:

• It is why the shape changed. The redesign traded a sterile single-use bag, which FDA's proposal would not accept as preserved claim 119verified, for a bag reused within one patient. That is the configuration the one cleared bag carries claim 122verified. But that clearance states no in-use period anyone could borrow claim 169verified, and the verified chemistry runs against room-temperature holding claim 96verified.
• The viability question depends on its answer. The number of sessions one bag serves sets the cost of every session claim 189unconfirmed claim 188unconfirmed. A buyer premium cannot be priced until it is known.
• It has no fallback inside the current shape. A head that fails on pressure can become a powered head, as a different device. A bag that cannot be kept open has no label left to carry claim 119verified.

The question leaves open whether a nurse would pick up the head at all, and whether a buyer would pay above saline. Those are the desirability and viability conditions, and an answer here does not settle them. Naming this question is not a recommendation, a gate, or a kill. It is the answer to "if a human could read only one more thing about this candidate, what should it answer".